Here, we report the case of recurrent swelling and pain in the proximal interphalangeal joint of the left ring finger, which was later diagnosed as a localized tenosynovial giant cell tumor in a young adult female. The first presentation was at the same anatomical site four years prior. Examination at presentation showed a firm skin-colored nodule in the volar aspect of the left ring finger. The swelling was seen to be partly attached to underlying structures and was non-tender. After a careful physical examination and plain radiograph imaging of the hand, the two differential diagnoses considered were tenosynovial giant cell tumor and ganglion cyst. A surgical excision was performed, and histopathologic evaluation showed features consistent with a tenosynovial giant cell tumor, localized type. The resection margins were clear of tumor. The patient had no intraoperative or postoperative complications. Postoperative physiotherapy was recommended. No recurrence was seen after postoperative surgical follow-up for one year. This report highlights the importance of histopathologic evaluation and confirmation of clear surgical margins in the management of tenosynovial giant cell tumors. In recurrent cases, surgical re-excision with clear margins provides good clinical outcomes. Before surgical excision, patients should be informed about the biologic nature of the lesion and the high risk of recurrence. The management modalities to prevent recurrence and the need for long-term follow-up should also be discussed with the patient.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006002PMC
http://dx.doi.org/10.7759/cureus.55962DOI Listing

Publication Analysis

Top Keywords

tenosynovial giant
20
giant cell
20
cell tumor
16
left ring
12
ring finger
12
localized tenosynovial
8
surgical excision
8
histopathologic evaluation
8
tenosynovial
5
giant
5

Similar Publications

Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should be considered. Total resection is preferable, but it can be challenging due to the risk of damaging the vertebral artery.

View Article and Find Full Text PDF

Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).

Expert Rev Anticancer Ther

December 2024

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Article Synopsis
  • Tenosynovial giant cell tumors (TGCTs) are aggressive tumors often found in younger individuals, leading to long-term disability and typically managed via surgery, which has its own risks.
  • This review focuses on systemic treatment options, particularly for the diffuse subtype (DT-TGCT), and assesses recent advancements and the historical context of these therapies.
  • Notable progress includes the development of CSF1 receptor-targeting therapies like pexidartinib, paving the way for further research on treatment effectiveness and optimizing patient outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • - Tenosynovitis with psammomatous calcifications (TPC) is a rare, non-cancerous condition that often affects women and is thought to result from repetitive use or trauma, commonly appearing at sites like the hands, feet, and wrists.
  • - In a study involving 18 new cases, most patients presented with painful masses, and imaging often showed benign characteristics, but many of these cases were misdiagnosed as more serious conditions like gout or tumors.
  • - Follow-up on patients (mostly for around 30 months) showed no local recurrences after surgical removal, highlighting the necessity for greater awareness among medical professionals regarding TPC.
View Article and Find Full Text PDF
Article Synopsis
  • Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
  • It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
  • Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!